Citations

Mayo Clinic

Clear

3030 citation(s) found for "Wu, Gregory F".

18 F-FDG PET in the Management of Patients with Anaplastic Thyroid Carcinoma
Bogsrud, Trond Velde , Karantanis, Dimitrios, Nathan, Mark A., Mullan, Brian P., Wiseman, Gregory A., Kasperbauer, Jan L. , Reading, Carl C., Lowe, Val J. , Hay, Ian

Thyroid® | July 17, 2008 | Volume: 18 | Issue: 7 | Pages: 713-719

10.1089/thy.2007.0350 | PMID 18630999 Get It

Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors in humans. The use of positron emission tomography (PET) with 18 F-fluorodeoxyglucose ( 18 F-FDG) in ATC has not been studied, and only a few case reports have been published. The objective of this study was to investigate the potential contribution of 18 F-FDG PET to the clinical management of patients with ATC. Methods: All patients with ATC studied with 18 F-FDG PET from August 2001 through March 2007 were included. The PET results were correlated with computed tomography, ultrasound, magnetic resonance imaging, bone scan, histology, and clinical follow-up. The FDG uptake was semiquantified as maximum standard uptake value. Any change in the treatment plan as a direct result of the PET findings as documented in the clinical notes was recorded. Results: Sixteen patients were included. True-positive PET findings were seen for all primary tumors, in all nine patients with lymph node metastases, in five out of eight patients with lung metastases, and in two patients with distant metastases other than lung metastases. In 8 of the 16 patients, the medical records reported a direct impact of the PET findings on the clinical management. Conclusions: ATC demonstrates intense uptake on 18 F-FDG PET images. In 8 of the 16 patients (50%), the medical records reported a direct impact of the PET findings on the management of the patient. PET may improve disease detection and have an impact on the management of patients with ATC relative to other imaging modalities.
Biologic and genetic characterization of the novel amyloidogenic lambda light chain–secreting human cell lines, ALMC-1 and ALMC-2
Arendt, Bonnie K., Ramı́rez-Alvarado, Marina , Sikkink, Laura A., Keats, Jonathan J. , Ahmann, Gregory , Dispenzieri, Angela , Fonseca, Rafaël , Ketterling, Rhett P. , Knudson, Ryan A., Mulvihill, Erin M., Tschumper, Renee C. , Wu, Xiaosheng , Zeldenrust, Steven R., Jelinek, Diane F., Dispenzieri, Angela , Ramirez-Alvarado, Marina , Ketterling, Rhett P , Keats, Jonathan J , Fonseca, Rafael

Blood | June 21, 2008 | Volume: 112 | Issue: 5 | Pages: 1931-1941

10.1182/blood-2008-03-143040 | PMID 18567838 Get It

AbstractPrimary systemic amyloidosis (AL) is a rare monoclonal plasma cell (PC) disorder characterized by the deposition of misfolded immunoglobulin (Ig) light chains (LC) in vital organs throughout the body. To our knowledge, no cell lines have ever been established from AL patients. Here we describe the establishment of the ALMC-1 and ALMC-2 cell lines from an AL patient. Both cell lines exhibit a PC phenotype and display cytokine-dependent growth. Using a comprehensive genetic approach, we established the genetic relationship between the cell lines and the primary patient cells, and we were also able to identify new genetic changes accompanying tumor progression that may explain the natural history of this patient's disease. Importantly, we demonstrate that free lambda LC secreted by both cell lines contained a beta structure and formed amyloid fibrils. Despite absolute Ig LC variable gene sequence identity, the proteins show differences in amyloid formation kinetics that are abolished by the presence of Na2SO4. The formation of amyloid fibrils from these naturally secreting human LC cell lines is unprecedented. Moreover, these cell lines will provide an invaluable tool to better understand AL, from the combined perspectives of amyloidogenic protein structure and amyloid formation, genetics, and cell biology.
Opportunities for Improving Management of Advanced Chronic Kidney Disease
Patwardhan, Meenal, Matchar, David B. , Samsa, Gregory P., Haley, William E.

American Journal of Medical Quality | June 6, 2008 | Volume: 23 | Issue: 3 | Pages: 184-192

10.1177/1062860608314985 | PMID 18539979 Get It

Development of a Novel Efficient Fluorescence-Based Plaque Reduction Microneutralization Assay for Measles Virus Immunity
Haralambieva, Iana H. , Ovsyannikova, Inna G. , Vierkant, Robert A. , Poland, Gregory A. , Vierkant, Robert A

Clinical and Vaccine Immunology | May 8, 2008 | Volume: 15 | Issue: 7 | Pages: 1054-1059

10.1128/cvi.00008-08 | PMID 18463223 Get It

ABSTRACT The measurement of functional measles virus-specific neutralizing antibodies is of considerable interest for vaccine-related research. In this study, we developed and standardized a simple, rapid, highly sensitive, and reproducible fluorescence-based plaque reduction microneutralization (PRMN) assay with visual and automated readout, using a recombinant measles virus engineered to express enhanced green fluorescent protein. The assay is performed in micro format, requires less time to complete (2 versus 4 to 7 days), and is less labor-intensive and less costly than the classical plaque reduction neutralization (PRN) test, widely accepted as the “gold standard” in measles serology. Two available WHO international anti-measles virus standards and one in-house reference serum were used to develop and standardize the new assay. The mean PRMN values from repeated assays were found to be similar to those reported in the literature or assigned to the WHO standards by the classical PRN assay. For validation, we used three groups of low, moderate, and high measles virus vaccine responders’ sera with moderate values of correlation in antibody levels (mIU/ml) between PRMN and the Dade Behring immunoglobulin G enzyme immunoassay (EIA). The PRMN assay was more sensitive at low antibody levels and more informative in terms of protection than this commercial EIA. In conclusion, we have developed and validated a sensitive and high-throughput measles virus-specific PRMN that can be readily used in large population-based measles studies.
An Evidence-Based Definition of Lifelong Premature Ejaculation: Report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation
McMahon, Chris G., Althof, Stanley E., Waldinger, Marcel D., Porst, Hartmut, Dean, John, Sharlip, Ira D., Adaikan, P.G., Becher, Edgardo, Broderick, Gregory A. , Buvat, Jacques, Dabees, Khalid, Hellstrom, Wayne J.G. , Incrocci, Luca , Laan, Ellen , Meuleman, E.J.H., Perelman, Michael A. , Rosen, Raymond C., Segraves, Robert, Buvat, Jacques, Giraldi, Annamaria , Giuliano, François , Rowland, David L.

The Journal of Sexual Medicine | May 6, 2008 | Volume: 5 | Issue: 7 | Pages: 1590-1606

10.1111/j.1743-6109.2008.00901.x | PMID 18466262 Get It

ABSTRACT Introduction The medical literature contains several definitions of premature ejaculation (PE). The most commonly quoted definition, the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision, and other definitions of PE are all authority based rather than evidence based, and have no support from controlled clinical and/or epidemiological studies. Aim The aim of this article is to develop a contemporary, evidence-based definition of PE. Methods In August 2007, the International Society for Sexual Medicine (ISSM) appointed several international experts in PE to an Ad Hoc Committee for the Definition of Premature Ejaculation. The committee met in Amsterdam in October 2007 to evaluate the strengths and weaknesses of current definitions of PE, to critique the evidence in support of the constructs of ejaculatory latency, ejaculatory control, sexual satisfaction, and personal/interpersonal distress, and to propose a new evidence-based definition of PE. Results The committee unanimously agreed that the constructs that are necessary to define PE are rapidity of ejaculation, perceived self-efficacy and control, and negative personal consequences from PE. The committee proposed that lifelong PE be defined as “. . . a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration, and the inability to delay ejaculation on all or nearly all vaginal penetrations, and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.” This definition is limited to men with lifelong PE who engage in vaginal intercourse. The panel concluded that there are insufficient published objective data to propose an evidence-based definition of acquired PE. Conclusion The ISSM definition of lifelong PE represents the first evidence-based definition of PE. This definition will hopefully lead to the development of new tools and Patient Reported Outcome measures for diagnosing and assessing the efficacy of treatment interventions and encourage ongoing research into the true prevalence of this disorder and the efficacy of new pharmacological and psychological treatments.
Human Leukocyte Antigen and Cytokine Receptor Gene Polymorphisms Associated With Heterogeneous Immune Responses to Mumps Viral Vaccine
Ovsyannikova, Inna G. , Jacobson, Robert M. , Dhiman, Neelam , Vierkant, Robert A. , Pankratz, V. Shane , Poland, Gregory A., Vierkant, Robert A , Jacobson, Robert M

Pediatrics | May 1, 2008 | Volume: 121 | Issue: 5 | Pages: e1091-e1099

10.1542/peds.2007-1575 | PMID 18450852 Get It

OBJECTIVES. Mumps outbreaks continue to occur throughout the world, including in highly vaccinated populations. Vaccination against mumps has been successful; however, humoral and cellular immune responses to mumps vaccines vary significantly from person to person. We set out to assess whether HLA and cytokine gene polymorphisms are associated with variations in the immune response to mumps viral vaccine.METHODS. To identify genetic factors that might contribute to variations in mumps vaccine–induced immune responses, we performed HLA genotyping in a group of 346 healthy schoolchildren (12–18 years of age) who previously received 2 doses of live mumps vaccine. Single-nucleotide polymorphisms (minor allele frequency of >5%) in cytokine and cytokine receptor genes were genotyped for a subset of 118 children.RESULTS. Median values for mumps-specific antibody titers and lymphoproliferative stimulation indices were 729 IU/mL and 4.8, respectively. Girls demonstrated significantly higher mumps antibody titers than boys, indicating gender-linked genetic differences in humoral immune response. Significant associations were found between the HLA-DQB1*0303 alleles and lower mumps-specific antibody titers. An interesting finding was the association of several HLA class II alleles with mumps-specific lymphoproliferation. Alleles of the DRB1 (*0101, *0301, *0801, *1001, *1201, and *1302), DQA1 (*0101, *0105, *0401, and *0501), and DQB1 (*0201, *0402, and *0501) loci were associated with significant variations in lymphoproliferative immune responses to mumps vaccine. Additional associations were observed with single-nucleotide polymorphisms in the interleukin-10RA, interleukin-12RB1, and interleukin-12RB2 cytokine receptor genes. Minor alleles for 4 single-nucleotide polymorphisms within interleukin-10RA and interleukin-12RB genes were associated with variations in humoral and cellular immune responses to mumps vaccination.CONCLUSIONS. These data suggest the important role of HLA and immunoregulatory cytokine receptor gene polymorphisms in explaining variations in mumps vaccine–induced immune responses.
The Physician on the Horns of a Dilemma
Loprinzi, Charles L. , Kalemkerian, Gregory P.

Journal of Clinical Oncology | April 29, 2008 | Volume: 26 | Issue: 13 | Pages: 2221-2222

10.1200/jco.2008.17.0035 Get It

Acute Stroke Imaging Research Roadmap
Wintermark, Max , Alexandrov, Andrei V. , Alger, Jeffry R. , Bammer, Roland , Baron, Jean‐Claude , Derdeyn, Colin P. , Donnan, Geoffrey A. , Eastwood, James D., Fiebach, Jochen B. , Fisher, Marc , Furie, Karen L. , Goldmakher, Gregory V., Hacke, Werner, Kidwell, Chelsea S., Kloska, Stephan P. , Köhrmann, Martin , Lee, Ting‐Yim , Lev, Michael H. , Liebeskind, David S. , Østergaard, Leif , Provenzale, James, Schellinger, Peter D. , Sorensen, A. Gregory , Wardlaw, Joanna M. , Wu, Ona , Warach, Steven , Albers, Gregory W. , Davis, Stephen M. , Demaerschalk, Bart M. , Koroshetz, Walter J. , Lees, Kennedy R. , Liebeskind, David S. , Powers, William J. , Silbergleit, Robert , Wardlaw, Joanna Marguerite , Wintermark, Max , Wu, Ona , Derdeyn, Colin P

Stroke | April 10, 2008 | Volume: 39 | Issue: 5 | Pages: 1621-1628

10.1161/strokeaha.107.512319 | PMID 18403743 Get It

The recent “Advanced Neuroimaging for Acute Stroke Treatment” meeting on September 7 and 8, 2007 in Washington DC, brought together stroke neurologists, neuroradiologists, emergency physicians, neuroimaging research scientists, members of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), industry representatives, and members of the US Food and Drug Administration (FDA) to discuss the role of advanced neuroimaging in acute stroke treatment. The goals of the meeting were to assess state-of-the-art practice in terms of acute stroke imaging research and to propose specific recommendations regarding: (1) the standardization of perfusion and penumbral imaging techniques, (2) the validation of the accuracy and clinical utility of imaging markers of the ischemic penumbra, (3) the validation of imaging biomarkers relevant to clinical outcomes, and (4) the creation of a central repository to achieve these goals. The present article summarizes these recommendations and examines practical steps to achieve them.
Attenuation of V- or C-Defective Measles Viruses: Infection Control by the Inflammatory and Interferon Responses of Rhesus Monkeys
Devaux, Patricia , Hodge, Gregory, McChesney, Michael B., Cattaneo, Roberto

Journal of Virology | April 3, 2008 | Volume: 82 | Issue: 11 | Pages: 5359-5367

10.1128/jvi.00169-08 | PMID 18385234 Get It

ABSTRACT Patients recruited in virus-based cancer clinical trials and immunocompromised individuals in need of vaccination would profit from viral strains with defined attenuation mechanisms. We generated measles virus (MV) strains defective for the expression of either the V protein, a modulator of the innate immune response, or the C protein, which has multiple functions. The virulence of these strains was compared with that of the parental wild-type MV in a natural host, Macaca mulatta . Skin rash, viremia, and the strength of the innate and adaptive immune responses were characterized in groups of six animals. Replication of V- or C-protein-defective viruses was short-lived and reached lower levels in peripheral blood mononuclear cells and lymphatic organs compared to the wild-type virus; none of the mutants reverted to the wild type. The neutralizing antibody titers and MV-specific T-cell responses were equivalent in monkeys infected with the viral strains tested, documenting strong adaptive immune responses. In contrast, the inflammatory response was better controlled by wild-type MV, as revealed by inhibition of interleukin-6 and tumor necrosis factor alpha transcription. The interferon response was also better controlled by the wild-type virus than by the defective viruses. Since V- and C-defective MVs induce strong adaptive immune responses while spreading less efficiently, they may be developed as vaccines for immunocompromised individuals. Moreover, MV unable to interact with single innate immunity proteins may be developed for preferential replication in tumors with specific contexts of vulnerability.